Munchen, Germany
smartbax is an innovative player in the Biotechnology sector, founded in 2021 and headquartered in Germany. The company is making significant strides against multi-drug resistant bacteria through the development of novel, multi-targeted antibacterial compounds. These compounds showcase extraordinary potency, specifically targeting challenging pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
In its most recent financial maneuver, smartbax secured a €4.70M Pre-Series A investment on October 22, 2025. This funding round was backed by a group of notable investors, including Bayern Kapital, Anobis Asset, UnternehmerTUM Funding for Innovators, HTGF – High-Tech Gründerfonds, and Boehringer Ingelheim Venture Fund (BIVF). These endorsements underscore the company's potential and credibility in addressing one of the critical challenges in modern medicine: combating antibiotic resistance.
